AzTrials
AzTrials

TumorPhase 3NCT00472303

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

A Phase 3 study testing Tapentadol Extended Release in people with Tumor and Pain, run by Grünenthal GmbH at 71 sites in 16 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Tumor, Pain
What is being tested?
Tapentadol Extended Release
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
622 participants
Where
71 sitesin 16 countries
Study dates
Jul 2007to Jun 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male and non-pregnant, non-lactating female subjects.
  • Of at least 18 years of age with chronic malignant tumor-related pain with a mean pain intensity (NRS) of 5 points or higher.
  • Subjects who are opioid-naïve or pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment.
  • Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control throughout the trial.
  • Expected course of the disease and the pain that would permit compliance with the trial protocol over the entire trial period.

Who cannot join

  • Subjects will be excluded from the study if they have a history of seizure disorder or epilepsy;
  • known history and/or presence of cerebral tumor or cerebral metastases.
  • history of alcohol or drug abuse;
  • uncontrolled hypertension,
  • clinical laboratory values reflecting severe renal insufficiency,
  • moderate or severe hepatic impairment,
Show all 12Show fewer
  • hepatitis B or C, HIV,
  • inadequate bone marrow reserve
  • currently treated with radiotherapy,
  • pain-inducing chemotherapy,
  • anti-parkinsonian drugs, neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine reuptake inhibitor (SNRI) or any other analgesic therapy than investigational medication or rescue medication during the trial.
  • selective serotonin reuptake inhibitor (SSRI) treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose.

Trial locations and contacts

71 sites in 16 countries.

71 sites in 16 countries

Czechia7 sites
  • Site 420005

    Brno, 62500

  • Site 420002

    České Budějovice, 37087

  • Site 420006

    Hradec Králové, 50005

  • Site 420007

    Liberec, 46063

  • Site 420008

    Olomouc, 77520

  • Site 420001

    Pilsen, 30460

  • Site 420004

    Prague, 18181

Other trials in Czechia

Germany7 sites
  • Site 049009

    Berlin, 12627

  • Site 049012

    Cologne, 50996

  • Site 049014

    Essen, 45122

  • Site 049007

    Löwenstein, 74245

  • Site 049020

    Potsdam, 14467

  • Site 049006

    Waldkirch, 79183

  • Site 049002

    Wiesbaden, 65185

Other trials in Germany

Hungary7 sites
  • Site 036001

    Debrecen, 4043

  • Site 036005

    Komárom, 2900

  • Site 036003

    Mátraháza, 3233

  • Site 036002

    Nyíregyháza, 4412

  • Site 036006

    Székesfehérvár, 8000

  • Site 036009

    Székesfehérvár, 8000

  • Site 036010

    Szekszárd, 7100

Other trials in Hungary

Romania7 sites
  • Site 040006

    Brasov, 500074

  • Site 040002

    Bucharest, 022328

  • Site 040003

    Bucharest, 022328

  • Site 040004

    Bucharest, 022328

  • Site 040005

    Cluj-Napoca, 400015

  • Site 040001

    Iași, 700106

  • Site 040007

    Timișoara, 300239

Other trials in Romania

Bulgaria6 sites
  • Site 359013

    Gabrovo, 5300

  • Site 359011

    Pleven, 5800

  • Site 359014

    Plovdiv, 4004

  • Site 359004

    Shumen, 9700

  • Site 359008

    Sofia, 1784

  • Site 359012

    Varna, 9003

Other trials in Bulgaria

Croatia6 sites
  • Site 385007

    Osijek, 31000

  • Site 385001

    Slavonski Brod, 35000

  • Site 385004

    Varaždin, 42000

  • Site 385006

    Zabok, 49210

  • Site 385002

    Zagreb, 10000

  • Site 385003

    Zagreb, 10000

Other trials in Croatia

Spain6 sites
  • Site 034009

    Barcelona, 08208

  • Site 034005

    Barcelona, 08221

  • Site 034006

    Mahón, 07703

  • Site 034012

    Pamplona, 31008

  • Site 034004

    Seville, 1013

  • Site 034002

    Valencia, 46014

Other trials in Spain

Russia5 sites
  • Site 007010

    Arkhangelsk, 163045

  • Site 007003

    Moscow, 125284

  • Site 007007

    Nizhny Novgorod, 603140

  • Site 007012

    Vladikavkaz, 362007

  • Site 007005

    Yaroslavl, 150054

Other trials in Russia

Serbia5 sites
  • Site 381003

    Belgrade, 11000

  • Site 381004

    Belgrade, 11000

  • Site 381005

    Belgrade, 11000

  • Site 381001

    Kamenitz, 21204

  • Site 381002

    Niš, 18000

Other trials in Serbia

Austria4 sites
  • Site 043004

    Klagenfurt, 9020

  • Site 043002

    Vienna, 1020

  • Site 043001

    Vienna, 1090

  • Site 043005

    Vienna, 1100

Other trials in Austria

Poland4 sites
  • Site 048004

    Bydgoszcz, 85796

  • Site 048005

    Gdansk, 80286

  • Site 048007

    Poznan, 60355

  • Site 048001

    Warsaw, 02781

Other trials in Poland

Moldova2 sites
  • Site 373001

    Chisinau, 2025

  • Site 373002

    Chisinau, 2025

Other trials in Moldova

Slovakia2 sites
  • Site 421005

    Banská Bystrica, 97517

  • Site 421001

    Košice, 04191

Other trials in Slovakia

France1 site
  • Site 033101

    Tarbes, 65000

Other trials in France

Italy1 site
  • Site 039001

    Naples, 80131

Other trials in Italy

Sweden1 site
  • Site 046001

    Stockholm, 17176

Other trials in Sweden

About this study

Official title: A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain

The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR).

*Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.

Read the detailed description

Normally chronic tumor related pain is controlled when participants receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. Tapentadol (CG5503), a newly synthesized drug with an prolonged release (PR) formulation, also acts as a centrally acting pain reliever but has 2 mechanisms of action. The aim of this trial is to investigate the effectiveness (level of pain control) and safety (side effects) of tapentadol (CG5503) PR compared with no drug (placebo) and corresponding dose of morphine (an opioid commonly used to treat tumor related pain). This trial is a randomized, double-blind (neither investigator nor patient will know which treatment was received), active- and placebo-controlled, parallel-group, randomized withdrawal design, multicenter trial.

The trial includes a 2 week titration phase starting with either 40 mg morphine (PR) bid (bid = twice daily dosing, one dose in the morning and one dose in the evening) or 100 mg tapentadol (CG5503) PR bid. Based on effectiveness and side effects subjects can up-titrate in steps of 50 mg tapentadol (CG5503 PR) to a maximal dose of 250 mg tapentadol (CG5503) PR bid or 100 mg morphine PR bid. If participants meet the stabilisation criteria at the end of the titration phase they will be re-randomized to either placebo or active treatment and will continue 4 weeks at the last dose level in the maintenance phase. Only participants on tapentadol in the titration phase will be re-randomized to either matching placebo or to tapentadol. To maintain the blinding nature of the trial participants in the morphine arm during the titration phase will also be re-randomized however they will all remain on morphine controlled release in the maintenance phase. Placebo to match tapentadol tablets, as well as placebo to match morphine capsules, will be used to mask the treatment allocation.

Participants will be issued with an electronic diary (eDiary) to capture Numeric Rating Scale (NRS) pain intensities.

Assessments of pain relief include the pain intensity numeric rating scale (NRS) and patient global impression of change (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, clinical laboratory tests and electrocardiograms. Venous blood samples will be collected for the determination of serum concentrations of tapentadol (CG5503).

Conditions
Tumor, Pain
Being tested
Tapentadol Extended Release, Matching Placebo after Tapentadol in the Titration Phase., Morphine Sulphate Controlled Release
Keywords
Opioid, Central acting analgesic, CG5503 PR, Tumor related pain, Cancer related pain, Morphine, Pain assessment, Placebo
Medical subject headings
Neoplasms, Pain, Cancer Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tapentadol Extended ReleaseDrug

    Also called Palexia, Nucynta, Yantil

    Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.

  • Matching Placebo after Tapentadol in the Titration Phase.Drug

    Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.

  • Morphine Sulphate Controlled ReleaseDrug

    Also called MST® CONTINUS®

    Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.

Study groups in NCT00472303
Study groupRoleWhat they receive
Matching Placebo after Tapentadol in Titration PhasePlacebo comparatorOral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
Receives: Drug: Tapentadol Extended Release; Drug: Matching Placebo after Tapentadol in the Titration Phase.
Morphine Controlled ReleaseActive comparatorOral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
Receives: Drug: Morphine Sulphate Controlled Release
Tapentadol Prolonged ReleaseExperimentalOral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses.
Receives: Drug: Tapentadol Extended Release

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Scored as Responder in Maintenance Phase.

    A "responder" is a participant in the study that:

    1. completed 28 days of the maintenance phase
    2. had a numeric rating scale score below 5 on the 11 point scale (where 0 indicates no pain and 10 indicates worst possible pain. This twice daily current pain score was averaged over Day 18 to Day 43.
    3. did not use more than 20 mg of rescue medication per day on average in the 28 day maintenance period (from Day 18 to Day 43).

    A participant that met all 3 of the above-mentioned criteria is counted as a responder, in other words the participant benefited from the assigned drug treatment. A participant that failed to meet only 1 of the 3 criteria is not counted as a responder.

    Measured: Day 18 through Day 43 (End of Maintenance Phase)

Secondary outcomes (22)
  1. Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Titration Phase in the Tapentadol Treatment Arm.

    Participants were asked to record their "average pain over the last 24 hours" pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".

    Measured: Day 1 through Day 14 (End of Titration Phase)

  2. Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Titration Phase in the Morphine Treatment Arm.

    Participants were asked to record their "average pain over the last 24 hours" pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".

    Measured: Day 1 through Day 14 (End of Titration Phase)

  3. Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Maintenance Phase.

    Participants were asked to record their "average pain over the last 24 hours" pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".

    Measured: Day 18 through Day 43 (End of Maintenance Phase)

  4. Current Pain Intensity Scores, Averaged Per Week, During the Titration Phase in the Tapentadol Arm.

    Participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".

    Measured: Day 1 through Day 14 (End of Titration Phase)

  5. Current Pain Intensity Scores, Averaged Per Week, During the Titration Phase in the Morphine Arm.

    Participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during the during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".

    Measured: Day 1 through Day 14 (End of Titration Phase)

  6. Current Pain Intensity Scores, Averaged Per Week by Treatment, During the Maintenance Phase.

    Participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during the 3 days prior to re-randomization or during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".

    Measured: Day 15 through Day 43 (End of Maintenance Phase)

  7. Use of Rescue Medication in the Titration Phase.

    The number of participants using rescue medication morphine sulfate immediate release 10 mg tablets in the titration phase were counted. This data was captured in an electronic diary.

    During the trial, morphine immediate release 10 mg was allowed as required without a maximum dose defined. However, participants were only re-randomized if their mean consumption of rescue medication was less or equal to 2 doses (20 mg) per day during the last 3 days of the titration phase).

    Measured: Day 1 through Day 14 (End of Titration Phase)

  8. Number of Participants Using Immediate Release Morphine Rescue Medication in the Maintenance Phase

    Participants were issued morphine 10 mg immediate release medication. The number of participants using rescue medication morphine sulfate immediate release 10 mg tablets in the maintenance phase were counted. This use of morphine immediate release was captured in each participant's electronic diary.

    Measured: Day 15 through Day 43 (End of Maintenance Phase)

  9. The Average Mean Total Daily Dose of Rescue Medication.

    Mean total daily dose of rescue medication morphine sulphate immediate release tablets in milligrams per day (mg/day).

    Measured: Day 1 (Start of Titration Phase) through Day 43 (End of Maintenance Phase)

  10. Changes in the Short Form 36® Health Survey (SF-36®) During the Titration Phase.

    The Short Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. Low scores on the Physical Component Summary measure indicate limitations in physical functioning, e.g. a high degree of bodily pain and physical limitations etc. For the Mental Component Summary measure, a low score is indicative of frequent psychological distress, social and role disability due to emotional problems etc. The theoretical range for the physical component score is 12.3279 to 59.6503. The theoretical range for the mental component score is 13.5313 to 59.6503. Positive values for changes in the component scores indicate an improvement.

    Measured: Day 1 (Start of Titration); Day 14 (End of Titration Phase)

  11. Changes in the Short Form 36® Health Survey (SF-36®) During the Maintenance Phase.

    The Short Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. Low scores on the Physical Component Summary measure indicate limitations in physical functioning, e.g. a high degree of bodily pain and physical limitations etc. For the Mental Component Summary measure, a low score is indicative of frequent psychological distress, social and role disability due to emotional problems etc. The theoretical range for the physical component score is 12.3279 to 59.6503. The theoretical range for the mental component score is 13.5313 to 59.6503. Positive values for changes in the component scores indicate an improvement.

    Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)

  12. Change in the EuroQoL (EQ-5D) Health Status Index (United Kingdom Time Trade-off Value Set) Change From Start of Titration to Endpoint Titration.

    The participant scores the EuroQol-5D. The EuroQoL-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1 = no problems, 2 = some problems, 3 = extreme problems).

    The responses to the five EQ-5D dimensions are scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. A positive change in the mean indicates that during this phase the health status improved. A positive change indicates an improvement in health. The minimal important difference is 0.074 (range -0.011 to 0.140).

    Measured: Day 1 (Start of Titration); Day 14 (End of Titration Phase)

  13. Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) Titration Phase.

    EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate better health. The values indicated represent the change from Day 1, a positive value indicates an improvement since the start of treatment.

    Measured: Day 1 (Start of Titration); Day 14 (End of Titration Phase)

  14. Change in the EuroQoL (EQ-5D) Health Status Index (United Kingdom Time Trade-off Value Set) Over Time in the Maintenance Phase for Tapentadol and the Placebo Randomized Withdrawal Treatment Arms.

    The participant scores the EuroQol-5D. The EuroQoL-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1 = no problems, 2 = some problems, 3 = extreme problems).

    The responses to the five EQ-5D dimensions are scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. A negative change in the mean indicates a worsening in health status since the beginning of the maintenance phase. A positive change indicates an improvement in health. The minimal important difference in the Health Status Index is 0.074 (range -0.011 to 0.140).

    Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)

  15. Changes in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) Maintenance Phase.

    EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from Day 15, a negative mean value indicates a worsening of health-related quality of life since the start of the maintenance phase.

    Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)

  16. Patient Global Impression of Change

    In the Patient Global Impression of Change (PGIC) the participant is asked "Since I began study treatment, my overall status is". The participant is asked to circle one of seven categories. Scores range from very much improved to very much worse. The question was asked at the end of the maintenance phase with reference to the start of the maintenance phase where the participant continued at the dose that was effective at the end of the Titration Phase.

    Measured: Day 43 (End of Maintenance Phase)

  17. Quality of Sleep (Sleep Questionnaire) in the Titration Phase.

    Participants were asked the following question: "Please rate the overall quality of your sleep last night?" The quality of sleep from the start of the titration phase to the end of the titration phase was measured. The participant could choose one of the following options: Excellent, good, fair and poor.

    Measured: Day 1 (Start of Titration); Day 14 (end of Titration Phase)

  18. Quality of Sleep (Sleep Questionnaire) During the Maintenance Phase of the Trial.

    Participants were asked the following question: "Please rate the overall quality of your sleep last night?" The quality of sleep from the start of maintenance to the completion of treatment is reported. The participant could choose one of the following options: Excellent, good, fair and poor.

    Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)

  19. Clinical Opioid Withdrawal Scale (COWS) at the End of the Titration Phase.

    This instrument was developed by the National Institute on Drug Abuse. The physical components of withdrawal are primarily evaluated and based on questions and clinical observations. The possible opioid withdrawal effects are assessed using the Clinical Opioid Withdrawal Score (COWS). The COWS is a clinician rated 11-item scale that primarily evaluates the physical components of opioid withdrawal and is based on questions and clinical observations. Responses are rated on a Likert-type scale ranging from 0 to 4 or 5 depending on the item. The total COWS score is the sum of all individual items.

    The following withdrawal categories are based on the total COWS score:

    • None: total score below 5;
    • Mild: total score from 5 to 12;
    • Moderate: total score 13 to 24;
    • Moderately Severe: total score 25 to 36;
    • Severe: total score above 36. The investigator completes the COWS after participants discontinued trial medication 2 to less than 5 days after last intake of trial medication.

    Measured: Day 14 (End of Titration Phase)

  20. Clinical Opioid Withdrawal Score (COWS) at the End of the Maintenance Phase.

    This instrument was developed by the National Institute on Drug Abuse. The physical components of withdrawal are primarily evaluated and based on questions and clinical observations. The possible opioid withdrawal effects are assessed using the Clinical Opioid Withdrawal Score (COWS). The COWS is a clinician rated 11-item scale that primarily evaluates the physical components of opioid withdrawal and is based on questions and clinical observations. Responses are rated on a Likert-type scale ranging from 0 to 4 or 5 depending on the item. The total COWS score is the sum of all individual items.

    The following withdrawal categories are based on the total COWS score:

    • None: total score below 5;
    • Mild: total score from 5 to 12;
    • Moderate: total score 13 to 24;
    • Moderately Severe: total score 25 to 36;
    • Severe: total score above 36. The investigator completes the COWS after participants discontinued trial medication 2 to less than 5 days after last intake of trial medication.

    Measured: Day 43 (End of Maintenance Phase)

  21. Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) During the Titration Phase

    The Constipation Assessment (PAC-SYM) is a 12-item self-report questionnaire that assesses the severity of symptoms of constipation. Participants are asked "How severe have each of these symptoms been in the last two weeks?" e.g. "Pain in your stomach". There are 3 subscales: 4 questions on Abdominal symptoms, 3 questions on rectal symptoms and 5 questions on stool symptoms. Responses are rated on a 5-point Likert Scale ranging from 0 (absence of symptom) to 4 (very severe symptoms). The changes in overall mean and in each of the mean sub-scores vary theoretically from -4 to +4 (where a change of +4 would indicate a change from not present to very severe symptom). If the changes in the overall or subscale mean scores are positive then there is a worsening in symptoms associated with constipation from the start to the end of the titration phase.

    Measured: Day 1 (Start of Titration); Day 14 (End of Titration Phase)

  22. Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) During the Maintenance Phase

    The Constipation Assessment (PAC-SYM) is a 12-item self-report questionnaire that assesses the severity of symptoms of constipation. Participants are asked "How severe have each of these symptoms been in the last two weeks?" e.g. "Pain in your stomach". There are 3 subscales: 4 questions on Abdominal symptoms, 3 questions on rectal symptoms and 5 questions on stool symptoms. Responses are rated on a 5-point Likert Scale ranging from 0 (absence of symptom) to 4 (very severe symptoms). The changes in overall mean and in each of the mean sub-scores vary theoretically from -4 to +4 (where a change of +4 would indicate a change from not present to very severe symptom). If the changes in the overall or subscale mean scores are positive then there is a worsening in symptoms associated with constipation from the start to the end of the maintenance phase. A negative mean change indicates an improvement.

    Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2007 (estimated)
  2. Study startJul 2007
  3. Primary completionJun 2012
  4. Study completionJun 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
622 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00472303
Sponsor's protocol ID
761101
Other IDs
2006-004997-28, KF5503/15
Status last verified
Oct 2019
First submitted
10 May 2007
Last updated
4 Nov 2019
Data monitoring committee
No

Publications

  • Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014 Jul-Aug;17(4):329-43.

    PubMed 25054392
  • Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Dogan C, Etropolski M, Eerdekens M. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. Eur J Pain. 2016 Oct;20(9):1513-8. doi: 10.1002/ejp.875. Epub 2016 Apr 7.

    PubMed 27062079

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tapentadol Extended Release in people with Tumor and Pain, run by Grünenthal GmbH at 71 sites in 16 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 71 sites in Czechia, Germany, Hungary, Romania, Bulgaria and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 7 May 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Scored as Responder in Maintenance Phase. (time frame: Day 18 through Day 43 (End of Maintenance Phase)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00472303, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in